Canada Still Dominates Global Cannabis Exports As Europe Gains Ground
Cannabis team reviewing global medical supply chain packaging
Canada remains the world's largest medical cannabis exporter, but its international lead is becoming harder to defend. Germany imported roughly 203 metric tons of medical cannabis in 2025, with about 93,000 kilograms coming from Canada and approximately 55,000 kilograms from Portugal. German demand continues to expand, but rising European production, stricter pharmaceutical expectations, reimbursement changes, and lower cost suppliers are reshaping the international medical cannabis supply chain.
Quick facts
• Germany imported roughly 203 metric tons of medical cannabis in 2025
• Canada supplied approximately 93,000 kilograms, making it Germany's largest foreign supplier
• Portugal supplied approximately 55,000 kilograms and remains one of Canada's strongest competitors
• Germany imported another 67,000 kilograms during the first quarter of 2026
• Canada exported approximately 276 metric tons of medical cannabis flower globally in 2025
• Canadian medical cannabis exports were valued at about C$643 million when extracts are included
• Portugal exported 66,305 kilograms during the first half of 2026, already exceeding its reported full year 2025 volume
• Denmark and South Africa are also becoming meaningful international suppliers
• Germany remains the world's largest medical cannabis import market
• Since July 30, 2026, dried cannabis flower is no longer reimbursable through Germany's statutory health insurance system
• European regulators are paying closer attention to where pharmaceutical manufacturing requirements begin during cultivation and post harvest processing
• The universal operator lesson is simple: international market leadership can disappear quickly when regulation, local production, pricing, and buyer preferences change
If international medical cannabis is part of your growth strategy, complete our quick Puro Risk intake form so you can map supply contracts, product compliance, inventory, transportation, insurance, and market access exposure before committing to long term export volume.
Why Canada still leads
Canadian producers built international scale earlier than most competitors.
Established cultivation capacity, reliable export infrastructure, pharmaceutical relationships, and years of experience moving regulated cannabis across borders gave Canadian companies an early advantage.
Canada exported approximately 276 metric tons of medical cannabis flower during 2025, according to figures cited by MJBizDaily.
Germany remains a critical destination.
Canadian companies supplied almost half of Germany's imported medical cannabis during 2025, making the relationship one of the most important trade corridors in the global regulated cannabis industry.
But early leadership does not guarantee permanent market share.
Why Portugal is becoming more important
Portugal has become one of Europe's most important cannabis cultivation, processing, and export hubs.
Its location inside the European Union gives operators access to a regional pharmaceutical framework and shorter distribution routes to major markets such as Germany.
Portugal exported 66,305 kilograms of medical cannabis during the first half of 2026, according to data cited by MJBizDaily. That volume already exceeded its reported full year 2025 exports.
For German importers, European supply can offer advantages involving logistics, regulatory familiarity, lead times, and potentially lower transportation costs.
Why EU GMP expectations could reshape sourcing
Quality standards may become one of the biggest competitive issues.
Canadian exporters have historically combined agricultural cultivation standards with pharmaceutical processing before final distribution into Europe.
German regulators are increasingly examining where agricultural activity ends and pharmaceutical manufacturing begins.
Guidance issued in Hesse during 2026 identified drying as a critical manufacturing step and indicated that GMP compliant processing should generally occur where cannabis is harvested.
That guidance is not a European Union wide rule, but it shows how regulatory interpretation could change sourcing decisions.
If more authorities require pharmaceutical standards earlier in production, facilities designed primarily around agricultural compliance may need additional investment.
Why Germany's reimbursement changes matter
Demand is growing, but not every part of the German market is expanding under the same conditions.
Since July 30, dried cannabis flower is no longer reimbursable through Germany's statutory health insurance system. Eligible patients may still receive other qualifying cannabis medicines, including standardized extracts and certain pharmaceutical products.
Flower can still exist within the medical market through other lawful purchasing pathways, but the reimbursement change could influence product mix and purchasing behavior.
For exporters focused heavily on flower, that creates another reason to diversify products and customers.
Why regional production threatens Canada's advantage
Europe is gradually building its own cannabis supply infrastructure.
Portugal and Denmark are already meaningful exporters. German companies are investing in domestic cultivation, while producers in South Africa and other lower cost regions are pursuing European opportunities.
As more suppliers meet required quality standards, buyers gain negotiating leverage.
That can pressure wholesale pricing and make long distance transportation less attractive.
If international competition is changing your pricing or production assumptions, complete the Puro Risk intake form to identify contract, inventory, transportation, compliance, and insurance exposure before renewing major commitments.
Conclusion
Canada still leads global medical cannabis exports, but the market is becoming increasingly regional and competitive.
Germany's continued growth creates substantial opportunity, yet Portugal, Denmark, South Africa, German domestic cultivation, and other emerging suppliers are giving European buyers more choices.
The universal operator lesson is straightforward. Export success depends on more than cultivation volume.
Quality systems, regulatory alignment, pricing, logistics, customer concentration, contracts, and proximity to market will increasingly determine which suppliers retain international market share.
Educational note: This article is for education only and is not legal, regulatory, medical, financial, investment, pharmaceutical, international trade, product compliance, tax, or insurance advice.
What to do this week
• Review international customer concentration and dependence on Germany
• Confirm current GMP and cultivation quality requirements for each destination market
• Compare Canadian landed costs against European and lower cost international supply
• Review long term supply contracts for pricing and minimum volume obligations
• Model demand changes resulting from German reimbursement rules
• Build scenarios for stronger European production and continued wholesale price compression
FAQ
How much medical cannabis did Germany import in 2025?
Germany imported roughly 203 metric tons of medical cannabis during 2025.
How much came from Canada?
Canada supplied approximately 93,000 kilograms, making it Germany's largest foreign supplier.
Which country is Canada's biggest European competitor?
Portugal is one of the strongest competitors and supplied approximately 55,000 kilograms to Germany during 2025.
Is German medical cannabis demand still growing?
Yes. Germany imported another approximately 67,000 kilograms during the first quarter of 2026.
Why are EU GMP requirements important?
European pharmaceutical standards can influence where cultivation, drying, processing, testing, and manufacturing occur. Changes in regulatory interpretation can therefore affect which foreign facilities remain commercially competitive.
What is the biggest operator takeaway?
Canada still has scale and experience, but international suppliers need competitive pricing, strong pharmaceutical quality systems, flexible contracts, diversified customers, and supply chains that can adapt as Europe develops more regional production.
Cannabis staff reviewing packaging for international distribution
You might also like
SOURCES
MJBizDaily, Canada Still Dominates Global Cannabis Exports, But Changes Are Coming Fast, August 24, 2026
MJBizDaily reports Germany's record medical cannabis imports, Canada's leading supply position, Portugal's expansion, Canadian global exports, changing German quality expectations, and increasing competition from Europe and other producing regions.
Health Canada, Importing And Exporting Cannabis
Health Canada confirms that Canadian cannabis imports and exports are limited to medical or scientific purposes and require permits under the federal cannabis regulatory framework.
National Association of Statutory Health Insurance Physicians, Cannabis Medicines
https://www.kbv.de/praxis/verordnungen/arzneimittel/cannabis
Official German guidance confirms that dried cannabis flower has not been reimbursable through statutory health insurance since July 30, 2026, while qualifying standardized extracts and certain cannabis medicines remain eligible under specified conditions.
Canada remains the world's largest medical cannabis exporter, but growing European production is beginning to challenge its lead. Germany's expanding market, Portugal's rapid export growth, stricter pharmaceutical standards, reimbursement changes, and new lower cost suppliers are reshaping international cannabis competition.